Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

53.27 +0.41 (+0.78%)
Streaming Delayed Price Updated: 3:07 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
45 46 Next >
News headline image
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More ↗
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
News headline image
Why Is Sierra Oncology (SRRA) Stock Up Today? ↗
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
Via InvestorPlace
News headline image
Sierra Oncology Stock Is Soaring: Here's Why ↗
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in... 
Via Benzinga
News headline image
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares ↗
GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
News headline image
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029 ↗
 
Via Benzinga
News headline image
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
Watch For Continued Gains In Shares Of GlaxoSmithKline PLC (GSK) ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
News headline image
Highly Rated GlaxoSmithKline Eyes Breakout After Racking Up Series Of Wins ↗
The move comes after the FDA shut down its Vir-partnered Covid antibody, however. 
Via Investor's Business Daily
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
Via Investor Brand Network
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
Via Investor Brand Network
News headline image
Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here ↗
 
Via Benzinga
News headline image
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial ↗
 
Via Benzinga
News headline image
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates? ↗
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier. 
Via Benzinga
News headline image
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
From GSK
Via Business Wire
News headline image
Good and Bad stock news ↗
Microsoft is down because of an FTC investigation of its possible anti-competitive moves. 
Via Talk Markets
News headline image
EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine ↗
 
Via Benzinga
News headline image
LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact ↗
 
Via Benzinga
News headline image
Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility ↗
Vir Biotechnology remains under pressure despite its looming addition to a new index. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Omicron BA.2 Variant Represents More Than 50% COVID-19 Cases, Says CDC Estimates: WSJ ↗
According to the Centers for Disease Control and Prevention estimates, the omicron BA.2 variant represents approximately 55% of new COVID-19 cases in the U.S., as signs suggest infections are edging... 
Via Benzinga
News headline image
FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV ↗
 
Via Benzinga
News headline image
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness ↗
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country 
Via Benzinga
News headline image
Monday Markets News ↗
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
News headline image
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant ↗
 
Via Benzinga
News headline image
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs ↗
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
Via InvestorPlace
News headline image
Drug makers, Scientists Working For Long COVID Treatments: Reuters ↗
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,  
Via Benzinga
News headline image
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag ↗
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
News headline image
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC ↗
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.